3Zeitler H,Zimmer-mann C,Nickening G,et al. Elevated serum concentrations of soluble adhesion molecules in coronar artery diseases and acute myocardial infarction[J]. Eur J Med Res, 1997,2(9) : 389-390.
4Ishibatory T, Kijima M, Yoko Yama K, et al. Expression of cytokine and adhesion molecule mRNA in atheroetomy Specimens from patients with coronary artery diseases[J]. J Pn Circ J, 1999,63 (4) : 249-252.
5Chu X, Shen M, Xie F, et al. An X chromosome-wide associa- tion analysis identifies variants in GPRI74 as a risk factor for Graves' disease[J]. J Med Genet,2013, 50(7):479-485.
6Lopes MH. Therapy with 121Ⅰ to hyperthyroidism Graves disease resolution: dose selection[J]. Arq Bras Endocrinol Metabol, 2007, 51(7) : 1031-1033.
7Charkes ND. Retreatment of Graves' disease with radioiodine131Ⅰ [J]. J Nucl Med,1999, 40(1): 215-216.
8Hautzel H, Piser E, Yazdan-Doust N, et al. Qualitative and quantitative impact of protective glucocorticoid therapy on the ef- fective 131Ⅰ half-life in radioiodine therapy for Graves disease[J]. J Nuel Med,2010,51(12) :1917-1922.
9Erdogan D, Guilu H, Yildrim E, et al. Low serum bilirubin levels are independently and inversely related to impaired flowmediated vasodilatation and increased carotid intimamedia thickness in both men and women [J]. Atheroscterosis, 2006, 184 (2) : 431 - 437 .
10Weber C, Schober A, Zemecke A. Chemokines . key regulators of mononuclear ceil recruitment in atherosclerotic vascular disease [J] . Arterioscler Thromb Vase Bioi, 2004, 24 ( 11 ): 1997 - 2008.
